MENU
+Compare
XPH
ETF ticker: NYSE ARCA
AS OF
Sep 26 closing price
Price
$47.02
Change
+$1.20 (+2.62%)
Net Assets
171.82M

XPH stock forecast, quote, news & analysis

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U... Show more

Category: #Health
XPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for XPH with price predictions
Sep 26, 2025

XPH in upward trend: price may jump up because it broke its lower Bollinger Band on September 12, 2025

XPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 36 cases where XPH's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 65 cases where XPH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on September 26, 2025. You may want to consider a long position or call options on XPH as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 50-day moving average for XPH moved above the 200-day moving average on August 26, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XPH advanced for three days, in of 300 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 220 cases where XPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for XPH moved out of overbought territory on September 08, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for XPH turned negative on September 04, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Intra-Cellular Therapies (NASDAQ:ITCI).

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").

Market Cap

The average market capitalization across the SPDR® S&P Pharmaceuticals ETF ETF is 52.42B. The market cap for tickers in the group ranges from 93.31M to 649.52B. LLY holds the highest valuation in this group at 649.52B. The lowest valued company is PLRX at 93.31M.

High and low price notable news

The average weekly price growth across all stocks in the SPDR® S&P Pharmaceuticals ETF ETF was 1%. For the same ETF, the average monthly price growth was -0%, and the average quarterly price growth was 12%. ZVRA experienced the highest price growth at 27%, while HRMY experienced the biggest fall at -15%.

Volume

The average weekly volume growth across all stocks in the SPDR® S&P Pharmaceuticals ETF ETF was -58%. For the same stocks of the ETF, the average monthly volume growth was 4% and the average quarterly volume growth was 15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 74
Price Growth Rating: 54
SMR Rating: 74
Profit Risk Rating: 77
Seasonality Score: -32 (-100 ... +100)
View a ticker or compare two or three
XPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
SPDR Series TrustOne Lincoln Street Cph0326Boston
Phone
N/A
Web
www.spdrs.com